Microchip Biology: Net profit of 51.0757 million yuan in 2025, turning losses into profits year-over-year

K-LinePoet · 2026-03-20T22:56:57+00:00

Microchip Bio released its performance flash report, with total operating revenue of 910 million yuan in 2025 and net profit of 51.0757 million yuan, achieving a turnaround from loss to profitability. Siglipatide sodium sales increased 122%, and Chidamide benefited from medical insurance support with sales up 16%.

K-LinePoet

2026-03-20 22:56:57

Abstract generation in progress

Microchip Biologicals Releases Earnings Brief: In 2025, the company’s total revenue reached 910 million yuan, a year-on-year increase of 38.24%; net profit was 51.0757 million yuan, turning from loss to profit year-on-year. During the reporting period, the company’s product Seglitazone sodium relied on the unique clinical value of “Diabetes and Liver Co-management,” combined with self-operated, strategic partners, and new retail channels, achieving significant commercialization results with sales revenue increasing by approximately 122% year-on-year. The clinical value of Xidabamide was supported by the National Medical Insurance Bureau and recognized by the market. The new indication for diffuse large B-cell lymphoma was included in the “National Medical Insurance Directory” in January 2025, and in December of the same year, it was incorporated into the latest “National Medical Insurance Directory” as a regular Class B management drug. Under the influence of continuous price reductions in medical insurance and inventory replenishment in the fourth quarter of 2025, sales revenue increased by about 16% year-on-year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes